Financial reports
10-Q
2023 Q3
Quarterly report
13 Feb 24
10-Q
2023 Q2
Quarterly report
13 Nov 23
10-Q
2023 Q1
Quarterly report
14 Aug 23
ARS
2023 FY
Annual report to shareholders
7 Aug 23
10-K
2023 FY
Annual report
28 Jun 23
10-Q
2022 Q3
Quarterly report
13 Feb 23
10-Q
2022 Q2
Quarterly report
14 Nov 22
10-Q
2022 Q1
Quarterly report
15 Aug 22
10-K
2022 FY
Annual report
28 Jun 22
10-Q
2021 Q3
Quarterly report
14 Feb 22
Current reports
8-K
Other Events
2 Apr 24
8-K
Results of Operations and Financial Condition
13 Feb 24
8-K
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
20 Dec 23
8-K/A
Financial Statements and Exhibits
20 Dec 23
8-K
Completion of Acquisition or Disposition of Assets
14 Dec 23
8-K
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
28 Nov 23
8-K
Other Events
27 Nov 23
8-K
Results of Operations and Financial Condition
13 Nov 23
8-K
Entry into a Material Definitive Agreement
23 Oct 23
8-K
Entry into a Material Definitive Agreement
29 Sep 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
6 Oct 23
S-3
Shelf registration
29 Sep 23
424B5
Prospectus supplement for primary offering
26 Sep 23
25-NSE
Exchange delisting
1 Sep 23
S-8
Registration of securities for employees
28 Jun 23
424B5
Prospectus supplement for primary offering
6 Feb 23
424B5
Prospectus supplement for primary offering
1 Feb 23
424B5
Prospectus supplement for primary offering
9 Nov 22
424B5
Prospectus supplement for primary offering
8 Nov 22
424B7
Prospectus with selling stockholder info
3 Oct 22
Other
EFFECT
Notice of effectiveness
10 Oct 23
UPLOAD
Letter from SEC
4 Oct 23
CORRESP
Correspondence with SEC
4 Oct 23
EFFECT
Notice of effectiveness
4 Oct 22
EFFECT
Notice of effectiveness
4 Oct 22
EFFECT
Notice of effectiveness
4 Oct 22
EFFECT
Notice of effectiveness
4 Oct 22
EFFECT
Notice of effectiveness
3 Aug 22
EFFECT
Notice of effectiveness
1 Apr 22
CORRESP
Correspondence with SEC
28 Mar 22